Multiple sclerosis (MS) is a devastating human autoimmune disease that primarily affects females in the third decade of life resulting in a variety of neurological symptoms including problems with motor function, vision, sphincter control and memory. MS is associated with inflammatory lesions in the central nervous system (CNS) that contain large numbers of cells from the immune system that are thought to contribute to the demyelination and axonal loss associated with the disease. Control of the CNS inflammation is critical to the control of MS symptoms and pathogenesis as it is the inflammatory response that is thought to directly cause the neurological symptoms and damage. Thus it is essential to understand how inflammation is controlled in the CNS if new targeted therapies are to be developed for MS treatment. In our studies using an animal model of MS, experimental autoimmune encephalomyelitis (EAE), we have observed that the B lymphocyte, or B cell, is required for recovery from disease symptoms. We have also observed that B cell expression of the co-stimulatory molecules B7 and CD40, and their production of IL-10 are required for recovery. We have also found that B7 expression is required for the timely appearance of Foxp3 T regulatory (Treg) cells and IL-10 in the CNS during EAE. These data demonstrate that B cells are required for the resolution of CNS inflammation. This proposal will investigate these B cell regulatory mechanisms by testing the following hypothesis: CD40-stimulated B cells activate a population of Treg cells via B7/CD28 and IL-10 in the periphery that in turn enter the CNS and suppress inflammation by an IL-10-dependent mechanism. This hypothesis will be tested by three aims: 1) To Identify the IL-10 producing B cell subset(s) required for EAE resolution;2) To identify the B cell-derived immunological signals that promote their production of IL-10 and the presence of IL-10 and Treg in the CNS;and 3) To Identify the T cell subset(s) that interact with the regulatory B cells. We will be identifying the IL-10-producing B cell subset;the regulatory mechanisms induced by B cell derived B7, CD40 and IL-10;the required T cell populations and the IL-10 producing cell in the CNS. Specifically, these studies are designed to determine how B cells either directly or indirectly through interactions with T cells, drive the resolution of inflammation in the CNS. Since little is known about how B cells regulate inflammation, these studies are likely to have an impact on multiple human inflammatory diseases, in addition to MS. It is our hope that the insight gained into how inflammation is regulated in the CNS will aid in the development of therapies for MS and other diseases that are inflammatory in nature.Public Health Relevance Statement In the central nervous system of multiple sclerosis patients the immune system facilitates the development of inflammatory lesions that result in permanent tissue damage resulting in disability if not resolved. B cells have been shown to regulate this autoimmune inflammation in the animal model of multiple sclerosis. This proposal will investigate the cellular mechanisms utilized by regulatory B cells in the resolution of central nervous system inflammation resulting in recovery from disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI069358-05
Application #
8225374
Study Section
Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section (HAI)
Program Officer
Esch, Thomas R
Project Start
2008-03-01
Project End
2014-02-28
Budget Start
2012-03-01
Budget End
2014-02-28
Support Year
5
Fiscal Year
2012
Total Cost
$399,391
Indirect Cost
$154,366
Name
Bloodcenter of Wisconsin, Inc.
Department
Type
DUNS #
057163172
City
Milwaukee
State
WI
Country
United States
Zip Code
53233
Strzepa, Anna; Pritchard, Kirkwood A; Dittel, Bonnie N (2017) Myeloperoxidase: A new player in autoimmunity. Cell Immunol 317:1-8
Zhang, Hao; Ray, Avijit; Miller, Nichole M et al. (2016) Inhibition of myeloperoxidase at the peak of experimental autoimmune encephalomyelitis restores blood-brain barrier integrity and ameliorates disease severity. J Neurochem 136:826-836
Ray, Avijit; Basu, Sreemanti; Gharaibeh, Raad Z et al. (2015) Gut Microbial Dysbiosis Due to Helicobacter Drives an Increase in Marginal Zone B Cells in the Absence of IL-10 Signaling in Macrophages. J Immunol 195:3071-85
Wang, L; Ray, A; Jiang, X et al. (2015) T regulatory cells and B cells cooperate to form a regulatory loop that maintains gut homeostasis and suppresses dextran sulfate sodium-induced colitis. Mucosal Immunol 8:1297-312
Ray, Avijit; Dittel, Bonnie N (2015) Interrelatedness between dysbiosis in the gut microbiota due to immunodeficiency and disease penetrance of colitis. Immunology 146:359-68
Ray, Avijit; Yuan, Cheng-Yin; Miller, Nichole M et al. (2015) 2B4 Is Dispensable for T-Dependent B Cell Immune Responses, but Its Deficiency Leads to Enhanced T-Independent Responses Due to an Increase in Peritoneal Cavity B1b Cells. PLoS One 10:e0137314
Malfitano, Anna Maria; Basu, Sreemanti; Maresz, Katarzyna et al. (2014) What we know and do not know about the cannabinoid receptor 2 (CB2). Semin Immunol 26:369-79
Ray, Avijit; Basu, Sreemanti; Miller, Nichole M et al. (2014) An increase in tolerogenic dendritic cell and natural regulatory T cell numbers during experimental autoimmune encephalomyelitis in Rras-/- mice results in attenuated disease. J Immunol 192:5109-17
Basu, Sreemanti; Ray, Avijit; Dittel, Bonnie N (2013) Differential representation of B cell subsets in mixed bone marrow chimera mice due to expression of allelic variants of CD45 (CD45.1/CD45.2). J Immunol Methods 396:163-7
Basu, Sreemanti; Ray, Avijit; Dittel, Bonnie N (2013) Cannabinoid Receptor 2 (CB2) Plays a Role in the Generation of Germinal Center and Memory B Cells, but Not in the Production of Antigen-Specific IgG and IgM, in Response to T-dependent Antigens. PLoS One 8:e67587

Showing the most recent 10 out of 17 publications